QuantLogix ← BIIB scorecard
📅 BIIB Earnings Preview
Biogen Inc. Common Stock
Next report (est.)
September 12, 2026
Countdown
91 days
EPS growth YoY
+31.1%
Revenue growth YoY
+1.9%
Implied vs actual — last 8 reports
ReportOptions impliedActual moveMarket was
April 29, 2026 ±2.8% +6.0% under-priced
October 30, 2025 ±1.8% +1.2% over-priced
July 31, 2025 ±2.3% +1.1% over-priced
May 1, 2025 ±2.4% -0.1% over-priced
October 30, 2024 ±2.3% -1.3% over-priced
August 1, 2024 ±4.5% -1.2% over-priced
April 24, 2024 ±2.0% +4.6% under-priced
November 8, 2023 ±2.6% -5.7% under-priced
Across these reports, options implied an average ±2.6% move vs an actual average of 2.6% — the stock stayed inside the implied band 63% of the time.
Fundamentals into the print
QuarterEPS (dil.)RevenueNet income
Q1 FY2026 $2.15 $2.5B $320M
Q4 FY2025 $-0.35 $2.3B $-49M
Q3 FY2025 $3.17 $2.5B $467M
Q2 FY2025 $4.33 $2.6B $635M
Analyst posture
Buy / Strong Buy
27
Hold
16
Sell
1
Strong upward revisions — 35 net (vs 32 prior)
Live 5-factor engine read: Buy · 63/100 Full scorecard →
Get alerted before every BIIB report — free Full live analysis
🤖 Pro runs a 10-agent AI debate on BIIB before the print — 5 analysts, bull vs bear, a risk read, and a trader's verdict. See Pro →

Biogen Inc. Common Stock (BIIB) reports in 91 days, with the next report estimated for September 12, 2026. Across the last 8 reports, options priced an average ±2.6% earnings move while the stock actually moved 2.6% on average — the market has been roughly fair on BIIB's earnings risk. Fundamentals into the print: EPS up 31.1% year-over-year, revenue up 1.9%. QuantLogix's live 5-factor engine currently reads BIIB as a buy at 63/100.

Implied move is derived from at-the-money option pricing; actual moves are close-to-close on report days. Next-report dates are estimates until confirmed by the company. Educational market analysis, not investment advice. Browse all signal scorecards →